# Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

> **NCT06968988** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Metastatic Soft-tissue Sarcoma

## Interventions

- **DRUG:** Zanzalintinib
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06968988
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2026-08-12
- **Final completion:** 2031-07-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06968988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06968988, "Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06968988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*